Sunil Patel, MD
Ophthalmology · Abilene, TXNPI 1760476964
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.1%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Kala Pharmaceuticals, Inc. at 53.1% of the total. Reporting peaked in 2020 at $15,409 and has fallen 96.6% since, to $529 in 2025. Among ophthalmology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 111 payments — averaging $259.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kala Pharmaceuticals, Inc.$15K
- F. Hoffmann-la Roche AG$8K
- US Oncology Corporate, Inc.$2K
- Roche TCRC, Inc.$927
- Genentech USA, Inc.$567
- AbbVie$345
- plus $2K from 23 others
Across 1,194 payments — averaging $9317.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$7.7M
- Regeneron$1.3M
- Eyepoint US, Inc.$768K
- Amgen$214K
- Apellis Pharmaceuticals, Inc.$198K
- AbbVie$185K
- plus $833K from 14 others
What the payments were for
- Consulting fees$15,30053%
- Speaking & faculty fees$7,95128%
- Travel & lodging$1,6276%
- Food & beverage$3,93214%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kala Pharmaceuticals, Inc. | 3 | $15,300 |
| F. Hoffmann-la Roche AG | 3 | $7,951 |
| US Oncology Corporate, Inc. | 3 | $1,571 |
| Roche TCRC, Inc. | 2 | $927 |
| Genentech USA, Inc. | 16 | $567 |
| AbbVie(2 entities) | 17 | $345 |
| Regeneron | 2 | $251 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $205 |
| Apellis Pharmaceuticals, Inc. | 7 | $183 |
| Regeneron Healthcare Solutions, Inc. | 7 | $164 |
| Novartis | 3 | $155 |
| Alcon | 1 | $123 |
| Eyepoint US, Inc. | 5 | $113 |
| Astellas Pharma US Inc | 4 | $103 |
| Harrow Eye, LLC | 5 | $100 |
| Genentech, Inc. | 2 | $100 |
| Thrombogenics, Inc. | 2 | $87 |
| Biotissue Holdings Inc. | 2 | $84 |
| Sandoz | 3 | $76 |
| ANI Pharmaceuticals, Inc. | 3 | $75 |
| Coherus Oncology, Inc. | 3 | $73 |
| Alimera Sciences, Inc. | 3 | $60 |
| Biogen | 3 | $47 |
| The Cameron-ehlen Group, Inc. | 1 | $44 |
| Bausch & Lomb Americas Inc. | 2 | $40 |
| Dutch Ophthalmic, USA | 1 | $22 |
| Neurotech Pharmaceuticals, Inc. | 1 | $22 |
| Amgen | 1 | $20 |
| Ocular Therapeutix, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYSUVIS$13,600
- Non-Covered Product$8,877
- INVELTYS$1,700
- SUSVIMO$149
- Constellation$123
- BUPARLISIB$122
- EYLEA$107
How this compares
$28,825 in reported general payments places this provider in the 90th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 369 | $12,313 |
| Bromfenac Sodium | 99 | $11,194 |
| ZirganGanciclovir | 25 | $11,064 |
| ProlensaBromfenac Sodium | 31 | $10,023 |
| Ketorolac Tromethamine | 245 | $7,781 |
| RestasisCyclosporine | 11 | $7,013 |
| CombiganBrimonidine Tartrate/Timolol | 17 | $5,853 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 45 | $5,526 |
| Brimonidine Tartrate | 435 | $4,956 |
| Cyclosporine | 11 | $4,270 |
| IlevroNepafenac | 11 | $3,911 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 215 | $3,848 |
| MoxifloxacinMoxifloxacin Hcl | 167 | $3,361 |
| Ofloxacin | 284 | $3,267 |
| Atropine Sulfate | 58 | $2,426 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Combigan | $345 | $12,86628 claims |
| Bausch & Lomb Americas Inc.Zirgan | $40 | $11,06425 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $205 | $10,02331 claims |
| NovartisIlevro | $155 | $3,91111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in Abilene
- Michael SingerSan Antonio$1.8M
- Oluwatosin SmithDallas$1.5M
- Charles WykoffBellaire$1.5M
- John MichelettiHouston$916K
- Davinder GroverDallas$705K
- Christina WengHouston$676K
- Peter ChangHouston$656K
- Zaina Al-MohtasebHouston$636K
- Ashkan AbbeyDallas$559K
- Stephen SladeHouston$530K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.